OptiNose — Q2 2021 Earnings Presentation
18 slides from OptiNose's earnings presentation, Aug 11, 2021
Slide 1: Building a Leading ENT / Allergy Specialty Company
Building a Leading ENT / Allergy Specialty Company C o r p o r a t e P r e s e n t a t i o n A u g u s t 1 1 , 2 0 2 1 Exhibit 99.2
Slide 2: Forward-Looking Statements
2 Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this
Slide 3: Key Takeaways and Q2 2021 Highlights
3 Key Takeaways and Q2 2021 Highlights Q2 2021 Performance Aligned with Company Guidance Multiple Factors Support Continued Revenue Growth in 2021 Enrollment Complete in First CS Trial with Data Expected in Q1 2022 Market Opportunity in CS is Significantly Larger than NP +79% XHANCE Net Revenue Grow
Slide 4: XHANCE New and Total Prescriptions
4 XHANCE New and Total Prescriptions XHANCE New Prescriptions increased 55% and Total Prescriptions increased 33% from Q2 2020 to Q2 2021 Estimated based on monthly prescription data from third parties and XHANCE preferred pharmacy network. The Market on this slide is defined as the sum of all intra
Slide 5: XHANCE Market Share & Prescribers by Prescribing Frequency
5 XHANCE Market Share & Prescribers by Prescribing Frequency The Market on this slide is defined as the sum of all intranasal steroid prescriptions written by physicians in the XHANCE target physician audience of approximately 18,000 physicians. Estimated based on monthly prescription data from thir
Slide 6: Q2 2021 Financial Update
optinose’_ SSS Q2 2021 Financial Update
Slide 7: Financial Review – Second Quarter 2021
7 Financial Review – Second Quarter 2021 XHANCE Net Revenue Increased 79% and Average Net Revenue per TRx Increased from $164 to $221 from Q2 2020 to Q2 2021 $10.3 $18.4 Q2 '20 Q2 '21 ($M) +79% $164 $221 Q2 '20 Q2 '21 +35% Net Revenue Average Net Revenue per TRx
Slide 8: Full Year 2021 Financial Guidance
8 Full Year 2021 Financial Guidance XHANCE Net Revenue and Average Net Revenue per Prescription ‒ FY 2021 expected to be at least $80 million ‒ FY 2021 average net revenue per prescription expected to exceed $200 Operating Expense (GAAP) expected to be between $137 – $142 million ‒ Approximately
Slide 9: Pipeline Updates
optinose’_ SSS Pipeline Updates
Slide 10: Chronic Sinusitis Pivotal Study Design Summary
10 EDS Placebo 372 μg Run-in to ensure ability to use patient symptom diary and presence of baseline symptoms Day 1 Week 24 Double Blinded Phase En d of St ud y Week 12Week 8 Chronic Sinusitis Pivotal Study Design Summary Randomized, double-blind, placebo-controlled, parallel-group, multicenter stud
Slide 11: XHANCE Chronic Sinusitis Program
11 XHANCE Chronic Sinusitis Program Enrollment in trial -3205 is complete In June we conducted a planned, blinded, interim analysis (IA) to assess variance in APOV (the CT scan co-primary endpoint) in trial -3205 – The observed variance in the IA is less than the variance assumed for the purpose
Slide 12: OPN-019 Pilot Study
12 OPN-019 Pilot Study In early July we received approval from regulatory authorities in Mexico to proceed with conduct of a randomized, adaptive proof of concept single-dose study to evaluate change in viral load after use of OPN-019 by adults with COVID-19 Study drug was made available in Mexi
Slide 13: Chronic Sinusitis and the Primary Care Opportunity
Chronic Sinusitis and the Primary Care Opportunity
Slide 14: Successful CS Development and a Primary Care Partner Could Enable Promotion of XHANCE
14 Successful CS Development and a Primary Care Partner Could Enable Promotion of XHANCE to up to 30 Million Patients Approximately 1 Million patients with nasal polyps (NP) are treated by specialty physicians who are the current focus of our sales call plans – Specialty physician preference share
Slide 15: Closing Remarks
optinose’_ SSS Closing Remarks
Slide 16: Key Takeaways and Q2 2021 Highlights
16 Key Takeaways and Q2 2021 Highlights Q2 2021 Performance Aligned with Company Guidance Multiple Factors Support Continued Revenue Growth in 2021 Enrollment Complete in First CS Trial with Data Expected in Q1 2022 Market Opportunity in CS is Significantly Larger than NP +79% XHANCE Net Revenue Gro
Slide 17: Investor Relations – Optinose
17 Investor Relations – NASDAQ: OPTN Optinose Investor Contact Jonathan Neely, VP, Investor Relations and Business Development 267-521-0531 [email protected] At 30 June 2021: – $94 million in cash – Long-term debt: $130 million – 53.1 million common shares o/s – 11.4 million options, warrants &
Slide 18: Building a Leading ENT / Allergy Specialty Company
Building a Leading ENT / Allergy Specialty Company C o r p o r a t e P r e s e n t a t i o n A u g u s t 1 1 , 2 0 2 1